EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Phase 2 Trial of PD ‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma

Yali Wang iD, Can Wang, Shuo Yin iD, Chunna Yu, Xiaojie Li iD, Xun Kang, Shoubo Yang iD, Wenting Xie iD, Yi Lin, Zhen Wu iD, Wenbin Li iD, Feng Chen iD

CNS Neuroscience & Therapeutics · 2025-12 · 31 (12)

DOI: 10.1111/cns.70659 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 08.12.2025. Verfasst von Yali Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Meningioma, Antibodies, Monoclonal, Humanized, Meningeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Key R&D Program of China, Beijing Clinical Key Specialty Project, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic therapeutic options for meningiomas remain limited. Emerging evidence indicates meningiomas harbor an immunosuppressive microenvironment and programmed cell death ligand 1 (PD‐L1) expression is significantly upregulated in both tumor cells and tumor‐infiltrating immune cells. Here we conducted a single‐arm, single‐center, open‐label, phase 2 clinical trial (NCT 04728568) evaluating the programmed cell death receptor‐1 (PD‐1) inhibitor sintilimab in patients with recurrent/progressive meningiomas following standard surgery and/or radiotherapy.

Methods

Forty patients (9 grade 1, 18 grade 2, and 13 grade 3) received intravenous sintilimab (200 mg every 3 weeks). According to Response Assessment in Neuro‐Oncology for meningioma (RANO‐meningioma) criteria, the 6‐month progression‐free survival rate (PFS‐6) was used as the primary endpoint. Secondary endpoints included the 12‐month progression‐free survival rate (PFS‐12), PFS, overall survival (OS), and safety. Peripheral lymphocyte subpopulations, tumor‐infiltrating lymphocyte (TIL) densities, and tumor mutational burden (TMB) were evaluated as immunocorrelated biomarkers.

Results

Patients with grade 1 exhibited a PFS‐6 of 67.0%, a PFS‐12 of 56.0%, and the median PFS was 14 months (95% CI: 0, 31.5). Grade 2/3 patients showed a PFS‐6 of 42.0%, a PFS‐12 of 19.0%, and the median PFS was 5.0 months (95% CI: 3.46, 6.54). The median OS was 27.0 months (95% CI: 17.26, 36.73) in grade 2/3 patients. The best outcome among all patients was stable disease (SD). Sintilimab was well tolerated without severe adverse events. A patient with a high TMB (13.14 muts/Mb) had a pseudoprogression with sintilimab and maintained stable disease among subsequent treatments. Among 3 patients with matched pre‐/post‐treatment tumor samples, 2 showed increased PD‐1+ T cell expression after sintilimab.

Conclusion

Sintilimab failed to improve PFS‐6 in both grade 1 and grade 2/3 recurrent/progressive meningiomas in this single‐arm, single‐center, and small‐sample trial. When evaluating PD‐1 inhibitor treatment for recurrent/progressive meningioma patients, who generally have a longer expected survival and high TMB, the use of the Immunotherapy Response Assessment in Neuro‐Oncology (iRANO) criteria may be more appropriate to avoid overlooking potential clinical benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaAntibodies, Monoclonal, HumanizedMeningeal NeoplasmsNeoplasm Recurrence, LocalImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedAgedAdultDisease Progression

Stichwörter der Autor:innen

PD‐1 inhibitormeningiomaphase 2 trialprogressiverecurrent

Substanzen

Antibodies, Monoclonal, HumanizedsintilimabImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Hepato-Pancreato-Biliary Center, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
  • Beijing Luhe Hospital, Capital Medical University, Beijing, China.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Yali Wang, Shuo Yin, Xiaojie Li, Shoubo Yang, Wenting Xie, Zhen Wu, Wenbin Li, Feng Chen

Förderung

  • The National Key R&D Program of China
  • Beijing Clinical Key Specialty Project
  • National Key Research and Development Program of China

Zitieren

APA

Wang, Y., Wang, C., Yin, S., Yu, C., Li, X., Kang, X., Yang, S., Xie, W., Lin, Y., Wu, Z., Li, W., & Chen, F. (2025). Phase 2 Trial of PD ‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma. CNS Neuroscience & Therapeutics, 31(12). https://doi.org/10.1111/cns.70659

Vancouver

Wang Y, Wang C, Yin S, Yu C, Li X, Kang X, et al. Phase 2 Trial of PD ‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma. CNS Neuroscience & Therapeutics. 2025;31(12). doi:10.1111/cns.70659

BibTeX
@article{Wang2025,
  author = {Wang, Yali and Wang, Can and Yin, Shuo and Yu, Chunna and Li, Xiaojie and Kang, Xun and Yang, Shoubo and Xie, Wenting and Lin, Yi and Wu, Zhen and Li, Wenbin and Chen, Feng},
  title = {Phase 2 Trial of PD ‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  volume = {31},
  number = {12},
  doi = {10.1111/cns.70659}
}
Kostenlos starten →